Menu
Search
|

Menu

Close
X

MiMedx Group Inc MDXG.OQ (NASDAQ Stock Exchange Capital Market)

7.83 USD
-1.05 (-11.82%)
As of Feb 23
chart
Previous Close 8.88
Open 9.01
Volume 3,338,002
3m Avg Volume 737,113
Today’s High 9.20
Today’s Low 7.61
52 Week High 18.24
52 Week Low 7.61
Shares Outstanding (mil) 112.47
Market Capitalization (mil) 1,364.26
Forward P/E 65.63
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
149
FY16
245
FY15
187
EPS (USD)
FY17
0.107
FY16
0.106
FY15
0.260
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
65.63
32.90
Price to Sales (TTM)
vs sector
4.82
5.77
Price to Book (MRQ)
vs sector
9.26
5.41
Price to Cash Flow (TTM)
vs sector
50.64
23.42
Total Debt to Equity (MRQ)
vs sector
0.01
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
14.78
14.43
Return on Equity (TTM)
vs sector
15.77
16.13

EXECUTIVE LEADERSHIP

Parker Petit
Chairman of the Board, Chief Executive Officer, Since 2009
Salary: $602,904.00
Bonus: --
William Taylor
President, Chief Operating Officer, Director, Since 2011
Salary: $502,170.00
Bonus: --
Michael Senken
Chief Financial Officer, Since 2010
Salary: $365,039.00
Bonus: --
Alexandra Haden
General Counsel, Secretary, Since 2015
Salary: $327,884.00
Bonus: --
Charles Koob
Director, Since 2008
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

1775 W Oak Commons Ct
MARIETTA   GA   30062-2254

Phone: +1678.3846720

MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

SPONSORED STORIES